The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the ongoing need for liquidity in the growth sectors, Abaxx Technologies and BriaCell Therapeutics have successfully closed their respective public equity offerings. Abaxx Technologies finalized a $69 million bought deal public offering priced at $54.25 per share. Simultaneously, BriaCell Therapeutics completed an offering of 1.45 million common shares, raising approximately $4.7 million in gross proceeds.
This capital raising activity comes as biotech and fintech firms navigate high operational costs and shifting investor sentiment. Abaxx utilized a structured 'bought deal' involving major underwriters like BMO Nesbitt Burns, signaling institutional support, while BriaCell employed a 'best-efforts' approach to secure its $4.7 million injection. Such offerings are common in these sectors to fund research and development without relying solely on debt, per market data and industry standards.
Sign in to access this content
Sign InInvestors should watch for the impact of share dilution on market pricing as these new shares enter circulation. Current macroeconomic conditions remain a factor, with the U.S. PCE Price Index showing a 3.8% annual increase as of the May 28, 2026 report. Future catalysts include upcoming employment and inflation data which will dictate the broader cost of capital for firms seeking further equity financing.